(Q38330746)

2 September 2017

title

Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment (English)

1 reference

2 September 2017

M Piazzi

10

0 references

author name string

M Y Follo

1

1 reference

2 September 2017

D Russo

2

1 reference

2 September 2017

C Finelli

3

1 reference

2 September 2017

S Mongiorgi

4

1 reference

2 September 2017

C Clissa

5

1 reference

2 September 2017

C Filì

6

1 reference

2 September 2017

C Colombi

7

1 reference

2 September 2017

M Gobbi

8

1 reference

2 September 2017

L Manzoli

9

1 reference

2 September 2017

A M Martelli

11

1 reference

2 September 2017

L Cocco

12

1 reference

2 September 2017

publication date

28 October 2011

1 reference

2 September 2017

1 reference

2 September 2017

volume

26

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

943-950

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.300

2 September 2017

exact match

0 references

cites work

Lipid signalling in disease.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Exploiting signal transduction pathways in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

The physiology and pathology of inositide signaling in the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Nuclear phospholipase C beta1 and cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Protein kinase C and other diacylglycerol effectors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

A unique function for cyclin D3 in early B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Cell cycle control genes and hematopoietic cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Epigenetic changes in the myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Molecular mechanisms involved in the progression of myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Hypomethylating agents and other novel strategies in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

The context and potential of epigenetics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Therapy with azanucleosides for myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

TRANSFAC: an integrated system for gene expression regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

DNA methylation and methyl-CpG binding proteins: developmental requirements and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Genomic DNA methylation: the mark and its mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

inferred from DOI database lookup

7 January 2021

based on heuristic

PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.300

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2011.300

1 reference

Dimensions Publication ID

2 September 2017

1007114345

0 references

1 reference